Lorenz C Hofbauer

List of Publications by Citations

338 papers	19,748 citations	65 h-index	131 g-index
393 ext. papers	22,645 ext. citations	7.4 avg, IF	6.85 L-index

#	Paper	IF	Citations
338	Osteoporosis: now and the future. *Lancet, The*, **2011**, 377, 1276-87	40	1443
337	The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. *Journal of Bone and Mineral Research*, **2000**, 15, 2-12	6.3	861
336	Romosozumab Treatment in Postmenopausal Women with Osteoporosis. *New England Journal of Medicine*, **2016**, 375, 1532-1543	59.2	725
335	Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. *JAMA - Journal of the American Medical Association*, **2004**, 292, 490-5	27.4	678
334	Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. *Endocrinology*, **1999**, 140, 4382-9	4.8	582
333	Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. *Endocrinology*, **1999**, 140, 4367-70	4.8	529
332	Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. *Bone*, **1999**, 25, 255-9	4.7	518
331	Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. *Journal of Molecular Medicine*, **2001**, 79, 243-53	5.5	424
330	Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. *Journal of Bone and Mineral Research*, **2009**, 24, 153-61	6.3	399
329	Osteoporosis in patients with diabetes mellitus. *Journal of Bone and Mineral Research*, **2007**, 22, 1317-28	6.3	344
328	Osteoporosis treatment: recent developments and ongoing challenges. *Lancet Diabetes and Endocrinology,the*, **2017**, 5, 898-907	18.1	315
327	RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2002**, 22, 549-53	9.4	315
326	The leukocyte integrin antagonist Del-1 inhibits IL-17-mediated inflammatory bone loss. *Nature Immunology*, **2012**, 13, 465-73	19.1	290
325	Increased osteoprotegerin serum levels in men with coronary artery disease. *Journal of Clinical Endocrinology and Metabolism*, **2003**, 88, 1024-8	5.6	274
324	Postmenopausal osteoporosis. *Nature Reviews Disease Primers*, **2016**, 2, 16069	51.1	263
323	Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. *Biochemical and Biophysical Research Communications*, **1998**, 250, 776-81	3.4	261
322	Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. *Biochemical and Biophysical Research Communications*, **2002**, 291, 680-6	3.4	243

321	Leptin reduces ovariectomy-induced bone loss in rats. *Endocrinology*, **2001**, 142, 3546-53	4.8	236
320	A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. *Osteoporosis International*, **2012**, 23, 2257-76	5.3	233
319	Bone, sweet bone--osteoporotic fractures in diabetes mellitus. *Nature Reviews Endocrinology*, **2012**, 8, 297-305	15.2	231
318	The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. *Endocrinology*, **2000**, 141, 4768-76	4.8	230
317	Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma. *Clinical Chemistry*, **2011**, 57, 411-20	5.5	225
316	RANK ligand and osteoprotegerin in myeloma bone disease. *Blood*, **2003**, 101, 2094-8	2.2	211
315	Vascular calcification and osteoporosis--from clinical observation towards molecular understanding. *Osteoporosis International*, **2007**, 18, 251-9	5.3	180
314	Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. *Biochemical and Biophysical Research Communications*, **2001**, 280, 334-9	3.4	180
313	Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-kappaB ligand in Mönckeberg's sclerosis and atherosclerosis. *Journal of Clinical Endocrinology and Metabolism*, **2004**, 89, 4104-12	5.6	166
312	Regenerative potential of glycosaminoglycans for skin and bone. *Journal of Molecular Medicine*, **2012**, 90, 625-35	5.5	146
311	Osteoprotegerin Serum Levels in Men: Correlation with Age, Estrogen, and Testosterone Status. *Journal of Clinical Endocrinology and Metabolism*, **2001**, 86, 3162-3165	5.6	146
310	Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases. *Cancer*, **2001**, 92, 460-70	6.4	144
309	miR-125b regulates calcification of vascular smooth muscle cells. *American Journal of Pathology*, **2011**, 179, 1594-600	5.8	143
308	Chiral spin liquid and emergent anyons in a Kagome lattice Mott insulator. *Nature Communications*, **2014**, 5, 5137	17.4	141
307	The circulating calcification inhibitors, fetuin-A and osteoprotegerin, but not matrix Gla protein, are associated with vascular stiffness and calcification in children on dialysis. *Nephrology Dialysis Transplantation*, **2008**, 23, 3263-71	4.3	138
306	Clinical review 114: hot topic. The role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases. *Journal of Clinical Endocrinology and Metabolism*, **2000**, 85, 2355-63	5.6	129
305	Calcitonin controls bone formation by inhibiting the release of sphingosine 1-phosphate from osteoclasts. *Nature Communications*, **2014**, 5, 5215	17.4	127
304	Inhibition of receptor activator of NF-kappaB ligand by denosumab attenuates vascular calcium deposition in mice. *American Journal of Pathology*, **2009**, 175, 473-8	5.8	121

303	Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study. *Bone*, **2014**, 58, 48-54	4.7	118
302	Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma. *Clinical Cancer Research*, **2003**, 9, 1436-40	12.9	113
301	The Role of Receptor Activator of Nuclear Factor-□B Ligand and Osteoprotegerin in the Pathogenesis and Treatment of Metabolic Bone Diseases. *Journal of Clinical Endocrinology and Metabolism*, **2000**, 85, 2355-2363	5.6	109
300	NADPH oxidase 4 limits bone mass by promoting osteoclastogenesis. *Journal of Clinical Investigation*, **2013**, 123, 4731-8	15.9	108
299	Prevention of glucocorticoid-induced bone loss in mice by inhibition of RANKL. *Arthritis and Rheumatism*, **2009**, 60, 1427-37		104
298	Exploring the biology of vascular calcification in chronic kidney disease: what□s circulating?. *Kidney International*, **2008**, 73, 384-90	9.9	102
297	Osteoprotegerin: a link between osteoporosis and arterial calcification?. *Lancet, The*, **2001**, 358, 257-9	40	100
296	Delayed bone regeneration and low bone mass in a rat model of insulin-resistant type 2 diabetes mellitus is due to impaired osteoblast function. *American Journal of Physiology - Endocrinology and Metabolism*, **2011**, 301, E1220-8	6	99
295	Androgen effects on bone metabolism: recent progress and controversies. *European Journal of Endocrinology*, **1999**, 140, 271-86	6.5	96
294	Interferon consensus sequence binding protein (ICSBP; IRF-8) antagonizes BCR/ABL and down-regulates bcl-2. *Blood*, **2004**, 103, 3480-9	2.2	94
293	Skeletal Metabolism, Fracture Risk, and Fracture Outcomes in Type 1 and Type 2 Diabetes. *Diabetes* , **2016**, 65, 1757-66	0.9	93
292	Estrogen Regulates Bone Turnover by Targeting RANKL Expression in Bone Lining Cells. *Scientific Reports*, **2017**, 7, 6460	4.9	91
291	Osteoprotegerin ligand and osteoprotegerin: novel implications for osteoclast biology and bone metabolism. *European Journal of Endocrinology*, **1999**, 141, 195-210	6.5	87
290	Sclerostin antibody treatment improves bone mass, bone strength, and bone defect regeneration in rats with type 2 diabetes mellitus. *Journal of Bone and Mineral Research*, **2013**, 28, 627-38	6.3	84
289	WNT5A is induced by inflammatory mediators in bone marrow stromal cells and regulates cytokine and chemokine production. *Journal of Bone and Mineral Research*, **2012**, 27, 575-85	6.3	83
288	Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease. *Calcified Tissue International*, **2004**, 74, 103-6	3.9	83
287	The role of osteoprotegerin and receptor activator of nuclear factor kappaB ligand in the pathogenesis and treatment of rheumatoid arthritis. *Arthritis and Rheumatism*, **2001**, 44, 253-9		83
286	Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts. *Journal of Clinical Endocrinology and Metabolism*, **2003**, 88, 4206-13	5.6	81

285	Gorham-Stout disease--stabilization during bisphosphonate treatment. *Journal of Bone and Mineral Research*, **2005**, 20, 350-3	6.3	81
284	Osteoprotegerin gene polymorphisms in men with coronary artery disease. *Journal of Clinical Endocrinology and Metabolism*, **2004**, 89, 3764-8	5.6	80
283	Medial arterial calcification in diabetes and its relationship to neuropathy. *Diabetologia*, **2009**, 52, 2478-88	10.3	75
282	Effects of androgens on the insulin-like growth factor system in an androgen-responsive human osteoblastic cell line. *Endocrinology*, **1999**, 140, 5579-86	4.8	75
281	Bone morphogenetic protein-6 production in human osteoblastic cell lines. Selective regulation by estrogen. *Journal of Clinical Investigation*, **1998**, 101, 413-22	15.9	74
280	Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets. *Lancet Diabetes and Endocrinology,the*, **2014**, 2, 830-42	18.1	73
279	Coagulation disorders in thyroid diseases. *European Journal of Endocrinology*, **1997**, 136, 1-7	6.5	71
278	Phytoestrogen genistein stimulates the production of osteoprotegerin by human trabecular osteoblasts. *Journal of Cellular Biochemistry*, **2002**, 84, 725-35	4.7	70
277	Approach to the patient with secondary osteoporosis. *European Journal of Endocrinology*, **2010**, 162, 1009-20	6.5	69
276	Selective glucocorticoid receptor modulation maintains bone mineral density in mice. *Journal of Bone and Mineral Research*, **2012**, 27, 2242-50	6.3	66
275	Endocrine aspects of bone metastases. *Lancet Diabetes and Endocrinology,the*, **2014**, 2, 500-12	18.1	65
274	Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients. *Osteoporosis International*, **2006**, 17, 693-703	5.3	65
273	Serum level of the phosphaturic factor FGF23 is associated with abdominal aortic calcification in men: the STRAMBO study. *Journal of Clinical Endocrinology and Metabolism*, **2012**, 97, E575-83	5.6	63
272	Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease. *Biochemical and Biophysical Research Communications*, **2005**, 338, 687-93	3.4	63
271	Effect of Vitamin D Supplementation, Omega-3 Fatty Acid Supplementation, or a Strength-Training Exercise Program on Clinical Outcomes in Older Adults: The DO-HEALTH Randomized Clinical Trial. *JAMA - Journal of the American Medical Association*, **2020**, 324, 1855-1868	27.4	62
270	An anti-inflammatory selective glucocorticoid receptor modulator preserves osteoblast differentiation. *FASEB Journal*, **2011**, 25, 1323-32	0.9	62
269	The role of osteoclast-associated receptor in osteoimmunology. *Journal of Immunology*, **2011**, 186, 13-8	5.3	62
268	Minireview: live and let die: molecular effects of glucocorticoids on bone cells. *Molecular Endocrinology*, **2009**, 23, 1525-31		60

267	Osteoprotegerin (OPG) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) levels in atherosclerosis. *Atherosclerosis*, **2006**, 184, 446-7	3.1	60
266	The effect of the degree of sulfation of glycosaminoglycans on osteoclast function and signaling pathways. *Biomaterials*, **2012**, 33, 8418-29	15.6	59
265	Interleukin-4 and interleukin-13 stimulate the osteoclast inhibitor osteoprotegerin by human endothelial cells through the STAT6 pathway. *Journal of Bone and Mineral Research*, **2008**, 23, 750-8	6.3	57
264	Atorvastatin stimulates the production of osteoprotegerin by human osteoblasts. *Journal of Cellular Biochemistry*, **2005**, 96, 1244-53	4.7	57
263	Myelodysplasia is in the niche: novel concepts and emerging therapies. *Leukemia*, **2015**, 29, 259-68	10.7	56
262	The anti-androgen hydroxyflutamide and androgens inhibit interleukin-6 production by an androgen-responsive human osteoblastic cell line. *Journal of Bone and Mineral Research*, **1999**, 14, 1330-7	6.3	56
261	Pituitary tumor size in acromegaly during pegvisomant treatment: experience from MR re-evaluations of the German Pegvisomant Observational Study. *European Journal of Endocrinology*, **2009**, 161, 27-35	6.5	55
260	Bone health during endocrine therapy for cancer. *Lancet Diabetes and Endocrinology,the*, **2018**, 6, 901-910	18.1	54
259	Mesenchymal stromal cells from patients with myelodyplastic syndrome display distinct functional alterations that are modulated by lenalidomide. *Haematologica*, **2013**, 98, 1677-85	6.6	54
258	Thyrotropin (TSH)-induced production of vascular endothelial growth factor in thyroid cancer cells in vitro: evaluation of TSH signal transduction and of angiogenesis-stimulating growth factors. *Journal of Clinical Endocrinology and Metabolism*, **2004**, 89, 6139-45	5.6	54
257	Therapy of osteoporosis in patients with Crohn's disease: a randomized study comparing sodium fluoride and ibandronate. *Alimentary Pharmacology and Therapeutics*, **2003**, 17, 807-16	6.1	54
256	Regulation of osteoprotegerin production by androgens and anti-androgens in human osteoblastic lineage cells. *European Journal of Endocrinology*, **2002**, 147, 269-73	6.5	54
255	Effects of parathyroid hormone on bone mass, bone strength, and bone regeneration in male rats with type 2 diabetes mellitus. *Endocrinology*, **2014**, 155, 1197-206	4.8	53
254	The German ACROSTUDY: past and present. *European Journal of Endocrinology*, **2009**, 161 Suppl 1, S3-S10	6.5	53
253	Osteoprotegerin and its cognate ligand: a new paradigm of osteoclastogenesis. *European Journal of Endocrinology*, **1998**, 139, 152-4	6.5	53
252	Pheochromocytoma - update on disease management. *Therapeutic Advances in Endocrinology and Metabolism*, **2012**, 3, 11-26	4.5	52
251	Thy-1 (CD90) promotes bone formation and protects against obesity. *Science Translational Medicine* , **2018**, 10,	17.5	51
250	Zoledronic acid induces apoptosis and changes the TRAIL/OPG ratio in breast cancer cells. *Cancer Letters*, **2010**, 287, 109-16	9.9	51

249	Inhibition of lamin A/C attenuates osteoblast differentiation and enhances RANKL-dependent osteoclastogenesis. *Journal of Bone and Mineral Research*, **2009**, 24, 78-86	6.3	50
248	Sulfated glycosaminoglycans support osteoblast functions and concurrently suppress osteoclasts. *Journal of Cellular Biochemistry*, **2014**, 115, 1101-11	4.7	49
247	The clinical, quality of life, and economic consequences of chronic anemia and transfusion support in patients with myelodysplastic syndromes. *Leukemia Research*, **2012**, 36, 525-36	2.7	47
246	Effects of oral contraceptives on circulating osteoprotegerin and soluble RANK ligand serum levels in healthy young women. *Clinical Endocrinology*, **2004**, 60, 214-9	3.4	46
245	Increased EPO Levels Are Associated With Bone Loss in Mice Lacking PHD2 in EPO-Producing Cells. *Journal of Bone and Mineral Research*, **2016**, 31, 1877-1887	6.3	46
244	High serum levels of Dickkopf-1 are associated with a poor prognosis in prostate cancer patients. *BMC Cancer*, **2014**, 14, 649	4.8	44
243	Tumour necrosis factor-related apoptosis-inducing ligand and osteoprotegerin serum levels in psoriatic arthritis. *Rheumatology*, **2006**, 45, 1218-22	3.9	44
242	VEGF-mediated angiogenesis of human pheochromocytomas is associated to malignancy and inhibited by anti-VEGF antibodies in experimental tumors. *Surgery*, **2002**, 132, 1056-63; discussion 1063	3.6	44
241	Correlates of bone microarchitectural parameters and serum sclerostin levels in men: the STRAMBO study. *Journal of Bone and Mineral Research*, **2013**, 28, 1760-70	6.3	43
240	Low serum levels of soluble RANK ligand are associated with the presence of coronary artery disease in men. *Circulation*, **2003**, 107, e76; author reply e76	16.7	43
239	Endocrine implications of human immunodeficiency virus infection. *Medicine (United States)*, **1996**, 75, 262-78	1.8	43
238	Sulfated hyaluronan improves bone regeneration of diabetic rats by binding sclerostin and enhancing osteoblast function. *Biomaterials*, **2016**, 96, 11-23	15.6	43
237	Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. *Journal of Clinical Endocrinology and Metabolism*, **2020**,	5.6	43
236	Effects of gonadal and adrenal androgens in a novel androgen-responsive human osteoblastic cell line. *Journal of Cellular Biochemistry*, **1998**, 71, 96-108	4.7	42
235	Soluble Interleukin-1 Receptor Antagonist Serum Levels in Smokers and Nonsmokers with GravesR Ophthalmopathy Undergoing Orbital Radiotherapy. *Journal of Clinical Endocrinology and Metabolism*, **1997**, 82, 2244-2247	5.6	41
234	Retinoic acid inhibits angiogenesis and tumor growth of thyroid cancer cells. *Molecular and Cellular Endocrinology*, **2007**, 264, 74-81	4.4	40
233	Denosumab for post-transplantation hypercalcemia in osteopetrosis. *New England Journal of Medicine*, **2012**, 367, 1766-7	59.2	39
232	Expression profile of WNT molecules in prostate cancer and its regulation by aminobisphosphonates. *Journal of Cellular Biochemistry*, **2011**, 112, 1593-600	4.7	39

231	Dissociation of osteogenic and immunological effects by the selective glucocorticoid receptor agonist, compound A, in human bone marrow stromal cells. *Endocrinology*, **2011**, 152, 103-12	4.8	39
230	Cholesterol and beyond - The role of the mevalonate pathway in cancer biology. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2020**, 1873, 188351	11.2	39
229	Induction of 3-hydroxy-3-methylglutaryl-CoA reductase mediates statin resistance in breast cancer cells. *Cell Death and Disease*, **2019**, 10, 91	9.8	38
228	Endocrine and clinical correlates of myostatin serum concentration in men--the STRAMBO study. *Journal of Clinical Endocrinology and Metabolism*, **2012**, 97, 3700-8	5.6	38
227	Effect of systemic glucocorticoid therapy on bone metabolism and the osteoprotegerin system in patients with active Crohn's disease. *European Journal of Gastroenterology and Hepatology*, **2003**, 15, 1165-70	2.2	38
226	Hyperthyroidism and Hypothyroidism in Male Mice and Their Effects on Bone Mass, Bone Turnover, and the Wnt Inhibitors Sclerostin and Dickkopf-1. *Endocrinology*, **2015**, 156, 3517-27	4.8	37
225	Bioinspired Collagen/Glycosaminoglycan-Based Cellular Microenvironments for Tuning Osteoclastogenesis. *ACS Applied Materials & Interfaces*, **2015**, 7, 23787-97	9.5	36
224	Transferrin receptor 2 controls bone mass and pathological bone formation via BMP and Wnt signaling. *Nature Metabolism*, **2019**, 1, 111-124	14.6	36
223	Orchiectomy upregulates free soluble RANKL in bone marrow of aged rats. *Bone*, **2009**, 45, 677-81	4.7	35
222	Osteoprotegerin gene polymorphism and the risk of osteoporosis and vascular disease. *Journal of Clinical Endocrinology and Metabolism*, **2002**, 87, 4078-9	5.6	35
221	Wnt5a is a key target for the pro-osteogenic effects of iron chelation on osteoblast progenitors. *Haematologica*, **2016**, 101, 1499-1507	6.6	35
220	Bone defect regeneration and cortical bone parameters of type 2 diabetic rats are improved by insulin therapy. *Bone*, **2016**, 82, 108-15	4.7	34
219	Immune Suppressive and Bone Inhibitory Effects of Prednisolone in Growing and Regenerating Zebrafish Tissues. *Journal of Bone and Mineral Research*, **2017**, 32, 2476-2488	6.3	34
218	Clinical and endocrine correlates of circulating sclerostin levels in patients with type 1 diabetes mellitus. *Clinical Endocrinology*, **2014**, 80, 649-55	3.4	34
217	Effects of the selective glucocorticoid receptor modulator compound A on bone metabolism and inflammation in male mice with collagen-induced arthritis. *Endocrinology*, **2013**, 154, 3719-28	4.8	34
216	Update on the impact of type 2 diabetes mellitus on bone metabolism and material properties. *Endocrine Connections*, **2019**, 8, R55-R70	3.5	34
215	Structural and functional insights into sclerostin-glycosaminoglycan interactions in bone. *Biomaterials*, **2015**, 67, 335-45	15.6	33
214	Skeletal and extraskeletal actions of denosumab. *Endocrine*, **2012**, 42, 52-62	4	33

213	Metabolic bone diseases in patients after allogeneic hematopoietic stem cell transplantation: report from the Consensus Conference on Clinical Practice in chronic graft-versus-host disease. *Transplant International*, **2011**, 24, 867-79	3	33
212	Nuclear factor of activated T cells mediates oxidised LDL-induced calcification of vascular smooth muscle cells. *Diabetologia*, **2011**, 54, 2690-701	10.3	33
211	Osteoprotegerin production by breast cancer cells is suppressed by dexamethasone and confers resistance against TRAIL-induced apoptosis. *Journal of Cellular Biochemistry*, **2009**, 108, 106-16	4.7	33
210	A novel resorption assay for osteoclast functionality based on an osteoblast-derived native extracellular matrix. *Journal of Cellular Biochemistry*, **2010**, 109, 1025-32	4.7	33
209	Osteoprotegerin expression in dendritic cells increases with maturation and is NF-kappaB-dependent. *Journal of Cellular Biochemistry*, **2007**, 100, 1430-9	4.7	33
208	Cytokine-induced osteoprotegerin expression protects pancreatic beta cells through p38 mitogen-activated protein kinase signalling against cell death. *Diabetologia*, **2007**, 50, 1243-7	10.3	33
207	p38 MAPK regulates the Wnt inhibitor Dickkopf-1 in osteotropic prostate cancer cells. *Cell Death and Disease*, **2016**, 7, e2119	9.8	32
206	WNT5A has anti-prostate cancer effects in vitro and reduces tumor growth in the skeleton in vivo. *Journal of Bone and Mineral Research*, **2015**, 30, 471-80	6.3	32
205	Artificial extracellular matrices with oversulfated glycosaminoglycan derivatives promote the differentiation of osteoblast-precursor cells and premature osteoblasts. *BioMed Research International*, **2014**, 2014, 938368	3	32
204	Long-term cyclic strain downregulates endothelial Nox4. *Antioxidants and Redox Signaling*, **2009**, 11, 2385-97	8.4	32
203	Serum measurement of osteoprotegerin--clinical relevance and potential applications. *European Journal of Endocrinology*, **2001**, 145, 681-3	6.5	32
202	Breast carcinoma cells modulate the chemoattractive activity of human bone marrow-derived mesenchymal stromal cells by interfering with CXCL12. *International Journal of Cancer*, **2015**, 136, 44-54	7.5	31
201	GRAND-4: the German retrospective analysis of long-term persistence in women with osteoporosis treated with bisphosphonates or denosumab. *Osteoporosis International*, **2016**, 27, 2967-78	5.3	31
200	Dickkopf-1 as a mediator and novel target in malignant bone disease. *Cancer Letters*, **2014**, 346, 172-7	9.9	31
199	The osteoclast-associated receptor (OSCAR) is a novel receptor regulated by oxidized low-density lipoprotein in human endothelial cells. *Endocrinology*, **2011**, 152, 4915-26	4.8	31
198	Denosumab for bone diseases: translating bone biology into targeted therapy. *European Journal of Endocrinology*, **2011**, 165, 833-40	6.5	31
197	In vitro and in vivo angiogenesis in PC12 pheochromocytoma cells is mediated by vascular endothelial growth factor. *Experimental and Clinical Endocrinology and Diabetes*, **2002**, 110, 386-92	2.3	31
196	Bone and mineral metabolism in human immunodeficiency virus infection. *Journal of Bone and Mineral Research*, **2001**, 16, 2-9	6.3	30

195	Insulin-like growth factor I messenger ribonucleic acid expression in porcine thyroid follicles is regulated by thyrotropin and iodine. *European Journal of Endocrinology*, **1995**, 132, 605-10	6.5	30
194	The PRIMARA study: a prospective, descriptive, observational study to review cinacalcet use in patients with primary hyperparathyroidism in clinical practice. *European Journal of Endocrinology*, **2014**, 171, 727-35	6.5	29
193	Osteonecrosis of the jaw after osteoporosis therapy with denosumab following long-term bisphosphonate therapy. *Mayo Clinic Proceedings*, **2013**, 88, 418-9	6.4	29
192	An appendix to the 2012 IOF-ECTS guidelines for the management of glucocorticoid-induced osteoporosis. *Archives of Osteoporosis*, **2012**, 7, 25-30	2.9	29
191	Dickkopf-1 is regulated by the mevalonate pathway in breast cancer. *Breast Cancer Research*, **2014**, 16, R20	8.3	28
190	Expression of receptor activator of NF-kappaB ligand (RANKL) mRNA in human multiple myeloma cells. *Journal of Cancer Research and Clinical Oncology*, **2004**, 130, 469-74	4.9	28
189	Isopropanolic extract of black cohosh stimulates osteoprotegerin production by human osteoblasts. *Journal of Bone and Mineral Research*, **2005**, 20, 2036-43	6.3	28
188	Oncologic resection achieving r0 margins improves disease-free survival in parathyroid cancer. *Annals of Surgical Oncology*, **2014**, 21, 1891-7	3.1	27
187	The promotion of osteoclastogenesis by sulfated hyaluronan through interference with osteoprotegerin and receptor activator of NF-B ligand/osteoprotegerin complex formation. *Biomaterials*, **2013**, 34, 7653-61	15.6	27
186	Regulation of bone mass and osteoclast function depend on the F-actin modulator SWAP-70. *Journal of Bone and Mineral Research*, **2012**, 27, 2085-96	6.3	27
185	Impact of long-term exposure to the tyrosine kinase inhibitor imatinib on the skeleton of growing rats. *PLoS ONE*, **2015**, 10, e0131192	3.7	27
184	Milk Fat Globule-Epidermal Growth Factor 8 (MFG-E8) Is a Novel Anti-inflammatory Factor in Rheumatoid Arthritis in Mice and Humans. *Journal of Bone and Mineral Research*, **2016**, 31, 596-605	6.3	27
183	Associations between serum 25-hydroxyvitamin D and bone turnover markers in a population based sample of German children. *Scientific Reports*, **2015**, 5, 18138	4.9	26
182	Postnatal Skeletal Deletion of Dickkopf-1 Increases Bone Formation and Bone Volume in Male and Female Mice, Despite Increased Sclerostin Expression. *Journal of Bone and Mineral Research*, **2018**, 33, 1698-1707	6.3	26
181	Ebf factors and MyoD cooperate to regulate muscle relaxation via Atp2a1. *Nature Communications*, **2014**, 5, 3793	17.4	26
180	Effect of aromatase inhibition on serum levels of sclerostin and dickkopf-1, bone turnover markers and bone mineral density in women with breast cancer. *Journal of Cancer Research and Clinical Oncology*, **2014**, 140, 1671-80	4.9	26
179	Pheochromocytoma and gastrointestinal stromal tumors in patients with neurofibromatosis type I. *American Journal of Medicine*, **2013**, 126, 174-80	2.4	26
178	Differential effects of cetuximab and AEE 788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid cancer cell lines. *Endocrine*, **2007**, 31, 105-13	4	26

177	Denosumab in postmenopausal women with osteoporosis and diabetes: Subgroup analysis of FREEDOM and FREEDOM extension. *Bone*, **2020**, 134, 115268	4.7	25
176	Severe abdominal aortic calcification in older men is negatively associated with DKK1 serum levels: the STRAMBO study. *Journal of Clinical Endocrinology and Metabolism*, **2014**, 99, 617-24	5.6	25
175	Targeting bone metabolism in patients with advanced prostate cancer: current options and controversies. *International Journal of Endocrinology*, **2015**, 2015, 838202	2.7	25
174	Osteoprotegerin: a new biomarker for impaired bone metabolism in complex regional pain syndrome?. *Pain*, **2014**, 155, 889-895	8	25
173	Detection and characterization of RANK ligand and osteoprotegerin in the thyroid gland. *Journal of Cellular Biochemistry*, **2002**, 86, 642-50	4.7	25
172	Differential effects of high-fat diet and exercise training on bone and energy metabolism. *Bone*, **2018**, 116, 120-134	4.7	24
171	Combined inhibition of the mevalonate pathway with statins and zoledronic acid potentiates their anti-tumor effects in human breast cancer cells. *Cancer Letters*, **2016**, 375, 162-171	9.9	23
170	Cathepsin S controls adipocytic and osteoblastic differentiation, bone turnover, and bone microarchitecture. *Bone*, **2014**, 64, 281-7	4.7	23
169	Crystallizing nanoparticles derived from vascular smooth muscle cells contain the calcification inhibitor osteoprotegerin. *Biochemical and Biophysical Research Communications*, **2011**, 407, 103-7	3.4	23
168	17beta-Estradiol inhibits osteoprotegerin production by the estrogen receptor-alpha-positive human breast cancer cell line MCF-7. *Biochemical and Biophysical Research Communications*, **2008**, 368, 736-41	3.4	23
167	Novel therapies in benign and malignant bone diseases. *Pharmacology & Therapeutics*, **2012**, 134, 338-44	13.9	22
166	Impact of lenalidomide on the functional properties of human mesenchymal stromal cells. *Experimental Hematology*, **2012**, 40, 867-76	3.1	22
165	The prevalence of familial hyperaldosteronism in apparently sporadic primary aldosteronism in Germany: a single center experience. *Hormone and Metabolic Research*, **2012**, 44, 215-20	3.1	22
164	Skeletal effects of cyclosporin A are gender related in rats. *Endocrinology*, **2003**, 144, 40-9	4.8	22
163	Disruption of a nuclear NFATc2 protein stabilization loop confers breast and pancreatic cancer growth suppression by zoledronic acid. *Journal of Biological Chemistry*, **2011**, 286, 28761-28771	5.4	21
162	Interleukin-4 differentially regulates osteoprotegerin expression and induces calcification in vascular smooth muscle cells. *Thrombosis and Haemostasis*, **2006**, 95, 708-714	7	21
161	Osteogenic Dkk1 Mediates Glucocorticoid-Induced but Not Arthritis-Induced Bone Loss. *Journal of Bone and Mineral Research*, **2019**, 34, 1314-1323	6.3	21
160	Seizures associated with zoledronic acid for osteoporosis. *Journal of Clinical Endocrinology and Metabolism*, **2011**, 96, 1955-9	5.6	20

159	Cortical bone status is associated with serum osteoprotegerin concentration in men: the STRAMBO study. *Journal of Clinical Endocrinology and Metabolism*, **2011**, 96, 2216-26	5.6	20
158	Graves Disease Associated With Autoimmune Thrombocytopenic Purpura. *Archives of Internal Medicine*, **1997**, 157, 1033		20
157	Glucocorticoids suppress Wnt16 expression in osteoblasts in vitro and in vivo. *Scientific Reports*, **2018**, 8, 8711	4.9	19
156	Multiple endocrine neoplasia type 2: recent progress in diagnosis and management. *European Journal of Endocrinology*, **1997**, 137, 572-8	6.5	18
155	Associations between ambient air pollution and bone turnover markers in 10-year old children: results from the GINIplus and LISAplus studies. *International Journal of Hygiene and Environmental Health*, **2015**, 218, 58-65	6.9	17
154	Concurrent antitumor and bone-protective effects of everolimus in osteotropic breast cancer. *Breast Cancer Research*, **2017**, 19, 92	8.3	17
153	The non-interventional BonViva Intravenous Versus Alendronate (VIVA) study: real-world adherence and persistence to medication, efficacy, and safety, in patients with postmenopausal osteoporosis. *Osteoporosis International*, **2014**, 25, 339-47	5.3	17
152	Krüppel-like factors KLF2 and 6 and Ki-67 are direct targets of zoledronic acid in MCF-7 cells. *Bone*, **2012**, 50, 723-32	4.7	17
151	Osteomyelosclerosis, anemia and extramedullary hematopoiesis in mice lacking the transcription factor NFATc2. *Haematologica*, **2011**, 96, 1580-8	6.6	17
150	Role of WNT5A receptors FZD5 and RYK in prostate cancer cells. *Oncotarget*, **2018**, 9, 27293-27304	3.3	17
149	Prognostic Value of RANKL/OPG Serum Levels and Disseminated Tumor Cells in Nonmetastatic Breast Cancer. *Clinical Cancer Research*, **2019**, 25, 1369-1378	12.9	17
148	Intercellular chatter: osteoblasts, osteoclasts and interleukin 6. *European Journal of Endocrinology*, **1996**, 134, 425-6	6.5	16
147	Development and characterization of a conditionally immortalized human osteoblastic cell line stably transfected with the human androgen receptor gene. *Journal of Cellular Biochemistry*, **1997**, 66, 542-51	4.7	16
146	TNF-related apoptosis-inducing ligand and its decoy receptor osteoprotegerin in nonischemic dilated cardiomyopathy. *Biochemical and Biophysical Research Communications*, **2005**, 338, 1745-50	3.4	16
145	Novel approaches to target the microenvironment of bone metastasis. *Nature Reviews Clinical Oncology*, **2021**, 18, 488-505	19.4	16
144	Increased pore size of scaffolds improves coating efficiency with sulfated hyaluronan and mineralization capacity of osteoblasts. *Biomaterials Research*, **2019**, 23, 26	16.8	16
143	Outcome of glucose homeostasis in patients with glucocorticoid-induced osteoporosis undergoing treatment with bone active-drugs. *Bone*, **2014**, 67, 175-80	4.7	15
142	Early detection of bone metabolism changes under different antiepileptic drugs (ED-BoM-AED)--a prospective multicenter study. *Epilepsy Research*, **2013**, 106, 417-22	3	15

141	Differential effects of mixed lymphocyte reaction supernatant on human mesenchymal stromal cells. *Experimental Hematology*, **2012**, 40, 934-44	3.1	15
140	Quantitative proteomics reveals novel functions of osteoclast-associated receptor in STAT signaling and cell adhesion in human endothelial cells. *Journal of Molecular and Cellular Cardiology*, **2012**, 53, 829-37	5.8	15
139	Serum myostatin levels are negatively associated with abdominal aortic calcification in older men: the STRAMBO study. *European Journal of Endocrinology*, **2012**, 167, 873-80	6.5	15
138	Osteopetrosis in cathepsin K-deficient mice. *European Journal of Endocrinology*, **1999**, 140, 376-7	6.5	14
137	Myelodysplastic syndromes and bone loss in mice and men. *Leukemia*, **2017**, 31, 1003-1007	10.7	13
136	Serum fetuin-A levels and abdominal aortic calcification in healthy men - The STRAMBO study. *Bone* , **2015**, 79, 196-202	4.7	13
135	Loss of milk fat globule-epidermal growth factor 8 (MFG-E8) in mice leads to low bone mass and accelerates ovariectomy-associated bone loss by increasing osteoclastogenesis. *Bone*, **2015**, 76, 107-14	4.7	13
134	Bone Formation and the Wnt Signaling Pathway. *New England Journal of Medicine*, **2016**, 375, 1902-1903	59.2	13
133	Zoledronic acid and atorvastatin inhibit -mediated adhesion of breast cancer cells. *Journal of Bone Oncology*, **2014**, 3, 10-7	4.5	13
132	The anti-progestin RU-486 inhibits viability of MCF-7 breast cancer cells by suppressing WNT1. *Cancer Letters*, **2011**, 312, 101-8	9.9	13
131	Combined use of 68Ga-DOTATATE and 18F-FDG PET/CT to localize a bronchial carcinoid associated with ectopic ACTH syndrome. *Journal of Clinical Endocrinology and Metabolism*, **2012**, 97, 2207-8	5.6	13
130	Functional thyrotropin receptor attenuates malignant phenotype of follicular thyroid cancer cells. *Endocrine*, **2006**, 30, 129-38		13
129	Functional Interference in the Bone Marrow Microenvironment by Disseminated Breast Cancer Cells. *Stem Cells*, **2016**, 34, 2224-35	5.8	13
128	Denosumab effects on bone density and turnover in postmenopausal women with low bone mass with or without previous treatment. *Bone*, **2019**, 120, 44-49	4.7	13
127	Interleukin-4 differentially regulates osteoprotegerin expression and induces calcification in vascular smooth muscle cells. *Thrombosis and Haemostasis*, **2006**, 95, 708-14	7	13
126	Effects of parathyroid hormone on cortical porosity, non-enzymatic glycation and bone tissue mechanics in rats with type 2 diabetes mellitus. *Bone*, **2016**, 82, 116-21	4.7	12
125	Monitoring of the first stages of bone healing with microdialysis. *Monthly Notices of the Royal Astronomical Society: Letters*, **2013**, 84, 76-81	4.3	12
124	Potentiated suppression of Dickkopf-1 in breast cancer by combined administration of the mevalonate pathway inhibitors zoledronic acid and statins. *Breast Cancer Research and Treatment*, **2015**, 154, 623-31	4.4	12

123	Probenecid as a sensitizer of bisphosphonate-mediated effects in breast cancer cells. *Molecular Cancer*, **2014**, 13, 265	42.1	12
122	Osteoprotegerin (OPG) and TNF-related apoptosis-inducing ligand (TRAIL) levels in malignant and benign pericardial effusions. *Clinical Biochemistry*, **2012**, 45, 237-42	3.5	12
121	Endocrinology meets immunology: T lymphocytes as novel targets for melatonin. *European Journal of Endocrinology*, **1996**, 134, 424-5	6.5	12
120	Microdialysis Sampling from Wound Fluids Enables Quantitative Assessment of Cytokines, Proteins, and Metabolites Reveals Bone Defect-Specific Molecular Profiles. *PLoS ONE*, **2016**, 11, e0159580	3.7	12
119	Erythropoietin inhibits osteoblast function in myelodysplastic syndromes via the canonical Wnt pathway. *Haematologica*, **2018**, 103, 61-68	6.6	12
118	More DATA to guide sequential osteoporosis therapy. *Lancet, The*, **2015**, 386, 1116-8	40	11
117	Paneling human thyroid cancer cell lines for candidate proteins for targeted anti-angiogenic therapy. *Journal of Cellular Biochemistry*, **2006**, 98, 954-65	4.7	11
116	Osteoprotegerin is highly expressed in the spinal cord and cerebrospinal fluid. *Acta Neuropathologica*, **2004**, 107, 575-7, author reply 578	14.3	11
115	Familial severe congenital neutropenia associated with infantile osteoporosis: a new entity. *American Journal of Hematology*, **2003**, 72, 34-7	7.1	11
114	Expression of bone-regulating factors osteoprotegerin (OPG) and receptor activator of NF-kappaB ligand (RANKL) in heterotopic vascular ossification. *Thrombosis and Haemostasis*, **2005**, 94, 1335-7	7	11
113	Gorham-Stout disease (phantom bone) of the shoulder girdle. *Rheumatology*, **1999**, 38, 904-5	3.9	11
112	The KISS1 Receptor as an In Vivo Microenvironment Imaging Biomarker of Multiple Myeloma Bone Disease. *PLoS ONE*, **2016**, 11, e0155087	3.7	11
111	WNT5A and Its Receptors in the Bone-Cancer Dialogue. *Journal of Bone and Mineral Research*, **2016**, 31, 1488-96	6.3	11
110	Emerging Players in Prostate Cancer-Bone Niche Communication. *Trends in Cancer*, **2021**, 7, 112-121	12.5	11
109	Thyroid Hormone Actions and Bone Remodeling - The Role of the Wnt Signaling Pathway. *Experimental and Clinical Endocrinology and Diabetes*, **2020**, 128, 450-454	2.3	10
108	Evolving functions of Dickkopf-1 in cancer and immunity. *Cancer Letters*, **2020**, 482, 1-7	9.9	10
107	Immunoadsorption Followed by Rituximab as a Definitive Treatment for Insulin Autoimmune Syndrome (Hirata Syndrome): A Case Report. *Diabetes Care*, **2018**, 41, e23-e24	14.6	10
106	Thyrotropin serum levels are differentially associated with biochemical markers of bone turnover and stiffness in women and men: results from the SHIP cohorts. *Osteoporosis International*, **2016**, 27, 719-27	5.3	10

105	Sclerostin Blockade and Zoledronic Acid Improve Bone Mass and Strength in Male Mice With Exogenous Hyperthyroidism. *Endocrinology*, **2017**, 158, 3765-3777	4.8	10
104	Osteometabolic and osteogenetic pattern of Turkish immigrants in Germany. *Experimental and Clinical Endocrinology and Diabetes*, **2012**, 120, 517-23	2.3	10
103	Regulation of sclerostin in glucocorticoid-induced osteoporosis (GIO) in mice and humans. *Endocrine Connections*, **2019**, 8, 923-934	3.5	10
102	Neuropilin-2 is an independent prognostic factor for shorter cancer-specific survival in patients with acinar adenocarcinoma of the prostate. *International Journal of Cancer*, **2020**, 146, 2619-2627	7.5	10
101	Effects of androgen excess and glucocorticoid exposure on bone health in adult patients with 21-hydroxylase deficiency. *Journal of Steroid Biochemistry and Molecular Biology*, **2020**, 204, 105734	5.1	10
100	Loss of Dkk-1 in Osteocytes Mitigates Alveolar Bone Loss in Mice With Periodontitis. *Frontiers in Immunology*, **2019**, 10, 2924	8.4	10
99	Monocytic expression of osteoclast-associated receptor (OSCAR) is induced in atherosclerotic mice and regulated by oxidized low-density lipoprotein in vitro. *Biochemical and Biophysical Research Communications*, **2013**, 437, 314-8	3.4	9
98	Graves disease associated with autoimmune thrombocytopenic purpura. *Archives of Internal Medicine*, **1997**, 157, 1033-1036		9
97	Glycosaminoglycans and their sulfate derivatives differentially regulate the viability and gene expression of osteocyte-like cell lines. *Journal of Bioactive and Compatible Polymers*, **2014**, 29, 474-485	2	8
96	Regulation of VEGF by mevalonate pathway inhibition in breast cancer. *Journal of Bone Oncology*, **2013**, 2, 110-5	4.5	8
95	Thy-1 Deficiency Augments Bone Loss in Obesity by Affecting Bone Formation and Resorption. *Frontiers in Cell and Developmental Biology*, **2018**, 6, 127	5.7	8
94	P38 regulates the Wnt inhibitor Dickkopf-1 in breast cancer. *Biochemical and Biophysical Research Communications*, **2015**, 466, 728-32	3.4	7
93	Loss of bone strength in HLA-B27 transgenic rats is characterized by a high bone turnover and is mainly osteoclast-driven. *Bone*, **2015**, 75, 183-91	4.7	7
92	Osteoprotegerin: a novel local player in bone metabolism. *European Journal of Endocrinology*, **1997**, 137, 345-6	6.5	7
91	The Role of Dickkopf-1 in Thyroid Hormone-Induced Changes of Bone Remodeling in Male Mice. *Endocrinology*, **2019**, 160, 664-674	4.8	6
90	Effects of adolescence-onset hypogonadism on metabolism, bone mineral density and quality of life in adulthood. *Journal of Pediatric Endocrinology and Metabolism*, **2015**, 28, 1047-55	1.6	6
89	Serum Profile of microRNAs Linked to Bone Metabolism During Sequential Treatment for Postmenopausal Osteoporosis. *Journal of Clinical Endocrinology and Metabolism*, **2020**, 105,	5.6	6
88	High serum levels of periostin are associated with a poor survival in breast cancer. *Breast Cancer Research and Treatment*, **2020**, 180, 515-524	4.4	6

87	Effects of rigosertib on the osteo-hematopoietic niche in myelodysplastic syndromes. *Annals of Hematology*, **2019**, 98, 2063-2072	3	6
86	Prediction of Fractures and Major Cardiovascular Events in Men Using Serum Osteoprotegerin Levels: The Prospective STRAMBO Study. *Journal of Bone and Mineral Research*, **2017**, 32, 2288-2296	6.3	6
85	Is there still a place for adrenal venous sampling in the diagnostic localization of pheochromocytoma?. *Endocrine*, **2011**, 40, 75-9	4	6
84	Multimodal therapy for vertebral involvement of systemic mastocytosis. *Spine*, **2009**, 34, E626-8	3.3	6
83	Dermatitis herpetiformis cured by hormone replacement for panhypopituitarism. *Endocrine Journal* , **1997**, 44, 437-40	2.9	6
82	Bone fragility in diabetes: novel concepts and clinical implications.. *Lancet Diabetes and Endocrinology,the*, **2022**,	18.1	6
81	Increased FGF-23 levels are linked to ineffective erythropoiesis and impaired bone mineralization in myelodysplastic syndromes. *JCI Insight*, **2020**, 5,	9.9	6
80	Greetings from below the aortic arch! The paradigm of cardiac paraganglioma. *Journal of Clinical Endocrinology and Metabolism*, **1996**, 81, 891-895	5.6	6
79	Alterations within the Osteo-Hematopoietic Niche in MDS and their Therapeutic Implications. *Current Pharmaceutical Design*, **2016**, 22, 2323-32	3.3	6
78	Mice lacking DKK1 in T□cells exhibit high bone mass and are protected from estrogen-deficiency-induced bone loss. *IScience*, **2021**, 24, 102224	6.1	6
77	Adjuvant tamoxifen but not aromatase inhibitor therapy decreases serum levels of the Wnt inhibitor dickkopf-1 while not affecting sclerostin in breast cancer patients. *Breast Cancer Research and Treatment*, **2017**, 164, 737-743	4.4	5
76	Effects of insulin therapy on porosity, non-enzymatic glycation and mechanical competence in the bone of rats with type 2 diabetes mellitus. *Bone*, **2016**, 91, 186-93	4.7	5
75	Are there still east-to-west differences in the incidence of hip fractures in Germany?. *Archives of Osteoporosis*, **2014**, 9, 195	2.9	5
74	Targeting syndecan-1 in breast cancer inhibits osteoclast functions through up-regulation of osteoprotegerin. *Journal of Bone Oncology*, **2014**, 3, 18-24	4.5	5
73	Mediastinal Parathyroid Tumor: Giant Adenoma or Carcinoma?. *Endocrine Pathology*, **1997**, 8, 161-166	4.2	5
72	Challenges in Preventing Bone Loss Induced by Aromatase Inhibitors. *Journal of Clinical Endocrinology and Metabolism*, **2020**, 105,	5.6	5
71	The Bone Morphogenetic Protein Pathway: The Osteoclastic Perspective. *Frontiers in Cell and Developmental Biology*, **2020**, 8, 586031	5.7	5
70	Soluble Neuropilin-1 is an independent marker of poor prognosis in early breast cancer. *Journal of Cancer Research and Clinical Oncology*, **2021**, 147, 2233-2238	4.9	5

69	Sclerostin Blockade-A Dual Mode of Action After All?. *Journal of Bone and Mineral Research*, **2016**, 31, 1787-1790	6.3	5
68	Interactions of Anemia, FGF-23, and Bone in Healthy Adults-Results From the Study of Health in Pomerania (SHIP). *Journal of Clinical Endocrinology and Metabolism*, **2021**, 106, e288-e299	5.6	5
67	Disruption of BMP Signaling Prevents Hyperthyroidism-Induced Bone Loss in Male Mice. *Journal of Bone and Mineral Research*, **2020**, 35, 2058-2069	6.3	4
66	Contributions of Dickkopf-1 to Obesity-Induced Bone Loss and Marrow Adiposity. *JBMR Plus*, **2020**, 4, e10364	3.9	4
65	Denosumab: a new treatment option for glucocorticoid-induced osteoporosis. *Lancet Diabetes and Endocrinology,the*, **2018**, 6, 428-429	18.1	4
64	Macroglossia as the only presenting feature of amyloidosis due to MGUS. *European Journal of Haematology*, **2014**, 92, 88-9	3.8	4
63	Calcification inhibitors in vascular calciphylaxis associated with normal renal function. *Thrombosis and Haemostasis*, **2012**, 108, 1241-3	7	4
62	Updating the metalloprotease nomenclature: bone morphogenetic protein 1 identified as procollagen C proteinase. *European Journal of Endocrinology*, **1996**, 135, 35-6	6.5	4
61	Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial **2009**, 24, 153		4
60	Basics of Bone Biology **2012**, 1-26		4
59	From Pharmacology to Physiology: Endocrine Functions of Opioid Receptor Networks. *Trends in Endocrinology and Metabolism*, **2021**, 32, 306-319	8.8	4
58	The Role of Inflammation in Breast and Prostate Cancer Metastasis to Bone. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	4
57	Disruption of the hepcidin/ferroportin regulatory circuitry causes low axial bone mass in mice. *Bone* , **2020**, 137, 115400	4.7	3
56	Associations of myeloid hematological diseases of the elderly with osteoporosis: A longitudinal analysis of routine health care data. *Leukemia Research*, **2018**, 69, 81-86	2.7	3
55	Site-Specific Variations in Bone Mineral Density under Systemic Conditions Inducing Osteoporosis in Minipigs. *Frontiers in Physiology*, **2017**, 8, 426	4.6	3
54	Vitamin D receptor knock-out mice: the expectational and the exceptional. *European Journal of Endocrinology*, **1998**, 138, 372-3	6.5	3
53	Human immunodeficiency virus infection and the thyroid gland. *European Journal of Endocrinology*, **1996**, 134, NP-674	6.5	3
52	New insights into the role of glycosaminoglycans in the endosteal bone microenvironment. *Biological Chemistry*, **2021**, 402, 1415-1425	4.5	3

51	Shaping the bone through iron and iron-related proteins. *Seminars in Hematology*, **2021**, 58, 188-200	4	3
50	Lack of CD45 in FLT3-ITD mice results in a myeloproliferative phenotype, cortical porosity, and ectopic bone formation. *Oncogene*, **2019**, 38, 4773-4787	9.2	3
49	Epo/EpoR signaling in osteoprogenitor cells is essential for bone homeostasis and Epo-induced bone loss. *Bone Research*, **2021**, 9, 42	13.3	3
48	Selective inhibition of receptor activator of NF-B ligand (RANKL) in hematopoietic cells improves outcome after experimental myocardial infarction. *Journal of Molecular Medicine*, **2018**, 96, 559-573	5.5	2
47	From Bone Cell Biology to Novel Therapies of Osteoporosis. *Drug Research*, **2015**, 65 Suppl 1, S14-5	1.8	2
46	Optimizing management of myelodysplastic syndromes post-allogeneic transplantation. *Expert Review of Hematology*, **2011**, 4, 669-80	2.8	2
45	Pulmonary metastases due to a giant-cell tumor of bone. *Journal of Clinical Endocrinology and Metabolism*, **2012**, 97, 3408-9	5.6	2
44	Identical twins with hypercalcaemia due to Lowe syndrome. *Rheumatology*, **2001**, 40, 107-8	3.9	2
43	Taking the message to the nucleus: MAD protein as a mediator of bone morphogenetic protein signaling. *European Journal of Endocrinology*, **1996**, 135, 654-5	6.5	2
42	Dorsomorphin: A novel inhibitor of Dickkopf-1 in breast cancer. *Biochemical and Biophysical Research Communications*, **2020**, 524, 360-365	3.4	2
41	Role of milk fat globule-epidermal growth factor 8 in osteoimmunology. *BoneKEy Reports*, **2016**, 5, 820		2
40	Impact Of The Tyrosine Kinase Inhibitors Imatinib, Dasatinib, and Bosutinib In Young Rats On The Vertebral Body. *Blood*, **2013**, 122, 1472-1472	2.2	2
39	Lack of the Thyroid Hormone Transporter Mct8 in Osteoblast and Osteoclast Progenitors Increases Trabecular Bone in Male Mice. *Thyroid*, **2020**, 30, 329-342	6.2	2
38	Tumor- and osteoclast-derived NRP2 in prostate cancer bone metastases. *Bone Research*, **2021**, 9, 24	13.3	2
37	Skeletal endocrinology: where evolutionary advantage meets disease. *Bone Research*, **2021**, 9, 28	13.3	2
36	Role of osteogenic Dickkopf-1 in bone remodeling and bone healing in mice with type I diabetes mellitus. *Scientific Reports*, **2021**, 11, 1920	4.9	2
35	Cancer-targeted therapies and radiopharmaceuticals. *BoneKEy Reports*, **2015**, 4, 707		1
34	Skeletal and soft tissue involvement in Mazabraud syndrome. *Journal of Clinical Endocrinology and Metabolism*, **2013**, 98, E1381-2	5.6	1

33	Hyperactive channels and inherited hypertension: Liddle's syndrome--an epithelial sodium channelopathy. *European Journal of Endocrinology*, **1997**, 136, 588-9	6.5	1
32	Less can be more--at least in mice: osteocalcin deficiency associated with increased bone formation. *European Journal of Endocrinology*, **1997**, 136, 586-7	6.5	1
31	Effects of vitamin D, omega-3 fatty acids and a simple home strength exercise program on fall prevention: the DO-HEALTH randomized clinical trial.. *American Journal of Clinical Nutrition*, **2022**,	7	1
30	Bone Metabolism in Cancer **2020**, 503-511		1
29	Skeletal health in patients following allogeneic hematopoietic cell transplantation. *Bone*, **2020**, 115684	4.7	1
28	Pharmacological mechanisms of therapeutics: Receptor activator of nuclear factor kappa B ligand inhibition **2020**, 1689-1710		1
27	Late-onset hypogonadism: Clinical evidence, biological aspects and evolutionary considerations. *Ageing Research Reviews*, **2021**, 67, 101301	12	1
26	Individualized Bone-Protective Management in Long-Term Cancer Survivors With Bone Metastases. *Journal of Bone and Mineral Research*, **2021**, 36, 1906-1913	6.3	1
25	Rodent Models of Spondyloarthritis Have Decreased White and Bone Marrow Adipose Tissue Depots. *Frontiers in Immunology*, **2021**, 12, 665208	8.4	1
24	Systemic PPARγ Antagonism Reduces Metastatic Tumor Progression in Adipocyte-Rich Bone in Excess Weight Male Rodents. *Journal of Bone and Mineral Research*, **2021**,	6.3	1
23	Effects of gonadal and adrenal androgens in a novel androgen-responsive human osteoblastic cell line **1998**, 71, 96		1
22	Bad to the Bone: The Effects of Therapeutic Glucocorticoids on Osteoblasts and Osteocytes.. *Frontiers in Endocrinology*, **2022**, 13, 835720	5.7	1
21	The mevalonate pathway in breast cancer biology. *Cancer Letters*, **2022**, 542, 215761	9.9	1
20	Deconstructing vitamin D deficiency. *Science Translational Medicine*, **2013**, 5, 193fs27	17.5	0
19	Antibodies targeting the calcium sensing receptor: acquired hypoparathyroidism--an autoimmune disease at last?. *European Journal of Endocrinology*, **1996**, 135, 172-3	6.5	0
18	Viscous hearing loss. *Lancet, The*, **1995**, 345, 1243	40	0
17	Evaluation of circulating Dickkopf-1 as a prognostic biomarker in ovarian cancer patients. *Clinical Chemistry and Laboratory Medicine*, **2022**, 60, 109-117	5.9	0
16	Luspatercept restores SDF-1-mediated hematopoietic support by MDS-derived mesenchymal stromal cells. *Leukemia*, **2021**, 35, 2936-2947	10.7	0

15	Bone cell-specific deletion of thyroid hormone transporter Mct8 distinctly regulates bone volume in young versus adult male mice.. *Bone*, **2022**, 159, 116375	4.7	0
14	Leopard skin. *Lancet Diabetes and Endocrinology,the*, **2020**, 8, 456	18.1	
13	Antibodies for the Treatment of Bone Diseases: Clinical Data **2016**, 239-255		
12	Of bone and genes: vitamin D receptor polymorphism and primary hyperparathyroidism. *European Journal of Endocrinology*, **1996**, 134, 685-6	6.5	
11	Cytokine inhibition: a new therapeutic avenue for skeletal diseases. *Drug Discovery Today*, **2002**, 7, 289	8.8	
10	How iodide gets access to thyrocytes: molecular details on the thyroid iodide transporter. *European Journal of Endocrinology*, **1996**, 135, 34-5	6.5	
9	Environmental endocrinology: hidden, but potent ways of activating the estrogen receptor. *European Journal of Endocrinology*, **1996**, 135, 653-4	6.5	
8	Bedeutung von RANK-Ligand und Osteoprotegerin f□den Knochenstoffwechsel **2006**, 479-509		
7	Basics of Bone Biology **2016**, 1-30		
6	Diabetes Mellitus and Osteoporosis **2011**, 103-108		
5	RANKL Inhibition: Clinical Data **2012**, 217-240		
4	Skeletal Effects of the Tyrosine Kinase Inhibitors Imatinib, Dasatinib, and Bosutinib in Young Rats. *Blood*, **2012**, 120, 4429-4429	2.2	
3	Interaktion von Tumorzellen und Knochen bei osteolytischen/osteosklerotischen Metastasen, Circulus vitiosus der Knochenmetastasierung **2014**, 13-21		
2	High stroma-derived WNT5A is an indicator for low-risk prostate cancer. *FEBS Open Bio*, **2021**, 11, 1186-1194	2.7	
1	Osteoporose bei Diabetes mellitus. *Diabetes Aktuell*, **2021**, 19, 178-183	0	